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Hepatitis B virus (HBV) infection has a low rate of chronicity compared to HCV infection, but chronic liver
inflammation can evolve to life threatening complications. Experimental data from HBV infected chimpanzees and
HBV transgenic mice have indicated that cytotoxic T cells are the main cell type responsible for inhibition of viral
replication, but also for hepatocyte lysis during chronic HBV infection. Their lower activation and impaired function
in later stages of infection was suggested as a possible mechanism that allowed for low levels of viral replication.
The lack of an interferon response in these models also indicated the importance of adaptive immunity in clearing
the infection. Increased knowledge of the signalling pathways and pathogen associated molecular patterns that
govern activation of innate immunity in the early stages of viral infections in general has led to a re-evaluation of
the innate immune system in HBV infection. Numerous studies have shown that HBV employs active strategies to
evade innate immune responses and induce immunosuppression. Some of the immune components targeted by
HBV include dendritic cells, natural killer cells, T regulatory cells and signalling pathways of the interferon response.
This review will present the current understanding of innate immunity in HBV infection and of the challenges
associated with clearing of the HBV infection.
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Introduction
Hepatitis B virus (HBV) is a noncytopathic, hepatotropic
virus of the Hepadnaviridae family that causes variable
degrees of liver disease in humans. Infection with HBV
can be either acute or chronic; while adult infections
have a relatively low rate of chronicity (around 5%), neo-
natal infections usually have a high persistence rate [1].
Chronic infection is mostly asymptomatic, but HBV car-
riers are at risk of developing life threatening cirrhosis
and later on hepatic carcinoma [2]. Despite the availabil-
ity of a prophylactic vaccine, HBV is estimated to infect
around 400 million people worldwide, with endemic
areas is Asia and Africa.
HBV replication itself is not directly cytotoxic to cells, as
seen in the large numbers of asymptomatic HBV carriers
who have minimal liver injury, despite ongoing intrahepatic
replication of the virus. The long-term aim in the treatment* Correspondence: abusca@toh.on.ca
1Departments of Pathology and Laboratory Medicine, University of Ottawa,
451 Smyth Road, Ottawa, Ontario K1H 8M5, Canada
Full list of author information is available at the end of the article
© 2014 Busca and Kumar; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.of these patients is to prevent the development of cirrhosis
and hepatocellular carcinoma [3]. The immune responses
to HBV antigens are responsible both for viral clearance
during acute infection and for disease pathogenesis. In
infected humans, viral clearance follows the develop-
ment of a vigorous immune response associated with
acute, self-limited inflammatory liver disease (acute viral
hepatitis). Immune responses involved in viral clearance
comprise both humoral and cellular immunity. Major-
histocompatibility-complex (MHC) class II–restricted,
CD4+ helper T cells contribute to generation of anti-
bodies against viral envelope antigens that clear circulating
virus particles. MHC class I–restricted, CD8+ cytotoxic T
lymphocytes eliminate infected cells [4].
Experimental approaches to HBV pathogenesis are ham-
pered because the host range of HBV is limited to man
and chimpanzees. The functional receptor for HBV has re-
cently been identified as sodium taurocholate cotransport-
ing polypeptide (NTCP), a molecule implicated in bile salts
transport [5]. A lot of experimental data has come from
studies with hepatitis B virus transgenic mice that harbour
viral antigens and replication-competent viral genomes inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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line DNA, therefore they are tolerant to HBV infection and
do not develop significant liver injury despite high levels of
replication [6]. These studies have shown the importance
of cytotoxic CD8+ lymphocytes (CTLs) in controlling viral
replication, as adoptively transferred virus-specific CTLs
can abolish HBV gene expression and replication in the
liver of HBV transgenic mice by causing acute liver injury
[7]. Moreover, transgenic mouse studies have shown that
liver disease has an immunological basis rather than being
virus mediated, with CTLs also playing a central part in
this process [8].
One way to overcome the inherent tolerance of HBV-
transgenic mice to viral antigens was to use human hepato-
cyte chimeric mice, where human hepatocytes repopulated
the liver of uPA/SCID mice, making it susceptible to HBV
infection [9]. This model is a valuable tool for studying
viral mutants and various therapeutic agents; however, the
lack of human immune cells also limits the study of in-
flammation and immunity.
Earlier studies in animal models failed to detect innate
immune responses in acute stages of HBV infection,
which led to a general consensus that HBV doesn’t in-
duce innate immunity during natural infection. Despite
of the development of a successful prophylactic vaccine,
a lot of immunpathological processes remain unknown,
especially with respect to chronic HBV infection. In this
setting, virus-specific CD8+ T are present in the liver,
but are impaired functionally or quantitatively so that
they are unable to clear the infection and likely contrib-
ute to disease pathogenesis [10]. This has rekindled the
interest in the innate immune responses and their im-
pact on viral biology.
It is now thought that host immune responses to viral
antigens and to viral replication in infected hepatocytes
are the main determinants of hepatocellular injury and
HBV pathogenesis. This review will focus on the deter-
minants of innate immunity in controlling viral replica-
tion and their contribution to viral pathogenesis, with
respect to both acute and chronic infection.
In general, innate immunity is important in controlling
infection immediately after contact with the pathogen, in
order to limit the spread of the infection and to initiate
efficient development of an adaptive immune response.
The innate immune system is activated by pathogens by
using pattern-recognition receptors (PRRs) that recognize
specific structures on pathogens, such as double-stranded
RNA and bacterial wall components. The most important
PRRs in viral infections are Toll-like receptors (TLRs), RNA
helicases, such as retinoic acid inducible gene I (RIG-I) and
melanoma differentiation associated gene 5 (MDA5), and
double stranded RNA-dependent protein kinase (PKR) [11].
Of the TLRs, TLR9 detects viral DNA, TLR7 and TLR8
identify viral single-stranded RNA, while TLR3 recognizesviral double-stranded RNA [12]. Following recognition
of virus associated molecular patterns by cellular PRRs,
recruitment of their distinct adaptor proteins will se-
quentially activate signalling cascades to induce cyto-
kine production in virus-infected cells.
The early phase of viral infections is mainly characterized
by the production of cytokines, type 1 interferon (IFN)-α/β,
and the activation of natural killer (NK) cells. Production of
type 1 IFNs can be triggered directly by virus replication
through cellular mechanisms that detect the presence of
viral RNA or DNA. The main sources of IFN-α/β are in-
fected cells and plasmacytoid dendritic cells, whereas IFN-γ
is produced primarily by NK and NKTcells [13].
Interferon response
Earlier studies have evaluated whether HBV has the abil-
ity to stimulate the interferon pathway of the innate im-
mune response during the early stage of infection. Data
from patients and animal models have shown that there
is a delay between HBV inoculation and efficient replica-
tion. Both HBV-DNA and HBV antigens become detect-
able around 5 weeks post-infection, after which viral
titers have a logarithmic expansion phase and HBV in-
fects most hepatocytes [14,15]. While it is tempting to
speculate that this initial lag of replication is a result of
efficient control of the virus by the innate immune re-
sponse, animal studies have indicated that this is not the
case, but rather that somehow the virus manages to evade
being recognized. In contrast to the immune response in
HCV infection, where expression of a large number of IFN-
regulated genes was rapidly induced in the liver of HCV-
infected chimpanzees [16], the same group has shown that
HBV did not cause any change in genes associated with
innate immune responses during acute HBV infection
of chimpanzees [17]. The authors concluded that HBV
did not induce an intrahepatic innate immune response
that could be detected in the infected animals because it
acts like a stealth virus early in infection, remaining un-
detected and spreading until the onset of the adaptive
immune response several weeks later. However, the
mechanisms by which HBV accomplishes this task are
less understood.
Interestingly, HBV replication is sensitive to the suppres-
sive effects of interferons in studies using the transgenic
mouse model or hepatoma cell lines. HBV was shown to
replicate in IFNγ KO and IFNα/β receptor KO mice at
levels higher than those observed in control mice, implying
that baseline levels of these cytokines control HBV replica-
tion in the absence of inflammation [18]. Also, expression
of adaptor proteins TRIF and MyD88 (TLR adaptor pro-
teins) and of IPS-1 (RIG-I/MDA5 adaptor protein) in hu-
man hepatoma cells was enough to limit HBV replication
by reducing the steady-state levels of viral mRNAs, in a
manner dependent on NF-κB transcription factor [19]. The
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replication was confirmed in another study showing that a
single intravenous injection of ligands specific for TLR3,
TLR4, TLR5, TLR7, and TLR9 was efficient to inhibit HBV
replication in a noncytolytical and IFNα/β dependent man-
ner in HBV transgenic mice [20].
Another characteristic of the interferon response in
HBV infection is that CD8+ T cells seem to control the
viral replication through an IFN-γ dependent mechan-
ism rather than direct cell killing of infected hepatocytes
[15]. The importance of noncytolytic T cell functions
was shown in a study where the onset of viral clearance
in HBV infected chimpanzees was tightly associated with
the appearance of virus-specific T cells and mRNA in
the liver, before the onset of hepatocyte destruction and
clinical hepatitis [21]. These results suggest that direct
cytological cell killing and IFN-γ secretion are function-
ally distinct mechanisms of CD8+ T cells that account
for control of hepatocyte destruction and viral replica-
tion, respectively.
Cytokines
Other cytokines have also been reported to control HBV
replication in the transgenic mouse model, including inter-
leukin 12 (IL-12) [22] and IL-18 [23], the effect being me-
diated by induction of IFN-γ and IFNα/β respectively.
Injection of HBV transgenic mice with CD40 ligand to in-
duce maturation of antigen presenting cells lead to recruit-
ment of macrophages, dendritic cells and NK cells to the
liver and induced secretion of TNF-α, IFN-γ, and IFNα/β,
which ultimately resulted in inhibition of HBV replication
[24]. In a primary human hepatocyte model, Hosel et al.
showed that briefly after infection, liver macrophages
recognize HBV and induce production of TNF-α, IL-6, IL-
8 and IL-1β. However, the ability to control viral replica-
tion was attributed to IL-6 via NF-κB activation [25].
Another major antiviral cytokine is TNF-α, which was
initially shown in HBV chimpanzee model to contribute
to the antiviral effects of CTLs alongside IFN-γ, although
initially the source of cytokines was unknown [7]. In the
HBV transgenic mouse model, TNF-α was secreted by
antigen presenting cells following activation as part of
the inflammatory cascade during acute infection [24].
Non-parenchymal liver cells like Kupfer macrophages
and liver sinusoidal endothelial cells are also part of the
innate immune response due to their ability to respond
to TLR signalling by producing various cytokines, in-
cluding TNF-α and IFN-β [26]. A recent report has also
shown that TNF-α and IL-1β can restrict HBV replica-
tion via activation of the NF-κB signaling pathway [27].
Early elevation of IL-10 and IP-10 has also been linked
with better outcome during HBV vaccination [28].
Taken together, these results suggest the existence of a
functional innate antiviral mechanism in hepatocytes thatis associated with favourable outcome in both acute and
chronic infections. Its activation under certain conditions
may also be used for therapeutic purposes. Activation of
innate immunity to induce interferon production but not
killing of infected hepatocytes may also represent a new
strategy for the treatment of chronic HBV infection, in the
absence of cytological cell death associated with the acti-
vation of CD8+ T cells.
Dendritic cells
DCs are major players in immune responses, due to their
ability to process foreign antigens and present them to ef-
fector cells. The presence of HBV or HBsAg during cyto-
kine induced maturation of dendritic cells resulted in a
more tolerogenic phenotype, as shown by a decreased T-
cell stimulatory capacity [29]. Other recently reported tar-
gets for HBV are plasmacytoid DCs (pDCs), which are
major components of the antiviral immune response, due
to their ability to secrete type 1 IFNs. However, HBV did
not activate human pDC in vitro, but HBV virions and
HBsAg were able to abrogate TLR7- and 9-induced IFNα
gene transcription by direct binding TLR9-triggered pDC
[30]. Also, TLR9-activated pDCs from HBV infected pa-
tients were impaired in their ability to induce cytolytic ac-
tivity of NK cells [31]. These studies indicate that the virus
exerts an immune regulatory effect that may directly con-
tribute to its persistence during chronic infection.
T regulatory cells
The immuno-modulatory properties of HBV are also re-
inforced by studies that show changes in the T regula-
tory cells (Tregs) population in HBV chronically infected
patients. CD4 +CD25+ Tregs normally maintain immune
tolerance against self and foreign antigens, due to their
ability to produce IL-10 and TGF-β. During chronic HBV
infection they seem to have a deleterious effect, because
they increase in number compared to acute infection or
healthy controls and this increase correlates with the viral
load, suggesting a direct effect on viral replication [32,33].
Generation of Tregs is also a mechanism by which pDCs
contribute to immunological tolerance in healthy individ-
uals [34]. This effect also contributes to the immune
suppression that characterizes chronic infection, since
pDCs from patients with chronic HBV infection were
able to generate a higher proportion of Tregs compared
to healthy controls [35].
Moreover, Tregs were capable of suppressing the pro-
liferation and IFN-γ production of autologous peripheral
blood mononuclear cells mediated by HBV antigen in vitro
[36], and increased numbers of Tregs were found in the
peripheral blood of patients with HBV related liver fail-
ure [37], suggesting that they play an active role in the
strategy employed by HBV to downregulate effector im-
mune responses.
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strategies employed by HBV includes its ability to affect
the production of IL-10, a cytokine with known immuno-
suppressive effects. HBcAg was able to induce significantly
higher IL-10 levels in peripheral blood mononuclear cells
from patients with chronic HBV infection compared to
those from healthy controls [38].
Monocytes, natural killer cells and NK T cells
In this setting of decreased activation of cytotoxic T
cells, there is a continuous stimulation of other cell types
that may explain the persistence of chronic infection and
subsequent liver inflammation that characterize chronic
HBV infection. The mechanism of chronic inflammation
involves recruitment of various cell types of the innate im-
mune system, including monocytes/macrophages and NK
cells [39]. Non-classical proinflammatory monocytes of
the CD14lowCD16+ phenotype have increased secretory
functions and the ability promote fibrosis in other inflam-
matory diseases and infections [40]. Their expression is in-
creased in both the peripheral blood and liver of patients
with chronic HBV infection, where they positively correl-
ate with liver inflammatory damage [41,42], suggesting
their active role in this process.
The lack of type 1 IFN responses in the setting of
in vivo infection seems surprising, given the fact that
the majority of infected individuals are able to resolve
the infection. This indicates that the viral replication
may be controlled by other arms of the innate immune
system.
Natural killer cells (NK cells) are the main effector popu-
lation involved in innate immune responses to viral infec-
tions. They exert antiviral activity through direct cytotoxic
effect or through the production of immunoregulatory
cytokines (IFN-γ, TNF-α, TGF-β, IL-10, etc). They are
identified by flow cytometry by the expression of CD56
and lack of T cells marker CD3. CD56+ NK cells also
express the FcγIII receptor CD16, which allows them
to mediate antibody-dependent cell-mediated cytotox-
icity [43]. NKT cells comprise a T cell subpopulation
characterized by expression of surface markers of NK
cells together with a T cell receptor that recognizes
glycolipids associated with MHC class I-like CD1 mol-
ecules [44].
Accumulating evidence indicates that NK cells are major
determinants of the clinical outcome following HBV infec-
tion. A study performed on two seronegative blood donors
who became positive for HBsAg and HBV DNA without
evidence of liver pathology, indicating successful contain-
ment of infection, were monitored throughout early stages
of infection. Their results indicate an early activation of
human innate immune system consisting of CD56+CD3–
NK and CD56+CD3+ NKT cells. These two cell types
were promptly activated before maximal HBV DNAelevation and HBV-specific T cell responses [45]. This
study suggested that early and efficient induction of in-
nate responses control the infection by non-cytolytic
mechanisms rather than by hepatocyte lysis and may
also contribute to timely induction of adaptive responses.
Moreover, augmentation of IFN-γ and IL-15 producing
CD56+ NK cells is also an immunomodulatory effect
of pegylated - IFN-α treatment during chronic HBV
infection [46].
These results are in contrast to those observed the
chimpanzee model [17] and may reflect differences be-
tween the two hosts. Studies on NK cell function early
in natural human infection are rare because the incuba-
tion period of HBV infection is always asymptomatic
and therefore difficult to study.
In a study looking at the response of NK and NKT cells
following vaccination with HBsAg, there was an increased
activation and IFN-γ production in NK and NKT cells fol-
lowing ex vivo incubation with recombinant HBsAg in re-
sponders to vaccination. These effects were not observed
in non-responders to the vaccine, suggesting that the two
cell types play an important role in the immune response
following hepatitis B vaccination by also contributing to a
robust adaptive immune response [47]. The ability of
NKT cells to control viral replication was also confirmed
in vivo. Upon activation of NKT cells with a glycolipid,
HBV replication was abolished and IFN-α, β and - γ were
detected in the liver of HBV transgenic mice [48]. More-
over, these effects persisted in the absence of conventional
CD4+ and CD8+ T cells [48], suggesting that the innate
immune response has the potential to contain the virus
during natural HBV infection.
However, activation of NK and NKT cells has also been
linked to liver injury in HBV transgenic mice, due to their
ability to secrete proinflammatory cytokines in the hepatic
microenvironment [49]. The involvement of NK activation
in liver injury was not observed in human studies. On the
contrary, one study comparing NK cell function in patients
with chronic HBV infection with those from chronic HCV
infection and healthy controls showed a more pronounced
functional defect in chronic HBV infection than in the
other two groups [50]. One recent study showed that NK
numbers and cytotoxic function are maintained in periph-
eral blood of patients with chronic HBV infection com-
pared to healthy controls, but their activation and cytokine
production abilities (IFN-γ and TNF-α) are impaired [51].
Overall, these studies indicate that the main function of
NK and NKT cells is to limit viral replication via cytokine
production rather than direct cytotoxicity and that func-
tion is compromised during chronic HBV infection, which
may contribute to viral persistence.
Although the exact contribution of NK and NKT cells
to chronic inflammation that characterizes chronic hepa-
titis B is yet to be established, the current literature suggest
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quent adaptive immune activation and control of viral rep-
lication in the absence of hepatocyte lysis. Inefficient
activation of the innate pathways gives rise to a lower,
but persistent proinflammatory activity that cannot clear
the infection and has deleterious effects on the liver
microenvirnment.
Viral strategies to counteract innate immune responses
Recent developments in our understanding of the HBV
infection have shown that the virus is not just a stealth
pathogen, but that it employs active mechanisms to avoid
recognition by the innate immune system. This may ex-
plain previous observations on its apparent inability to be
detected by PRRs.
As mentioned, RNA helicases, such as RIG-I and MDA5
are important PRRs responsible for recognition of viral
RNAs produced during viral infection and they represent
targets for immunosupression during HBV infection [52].
Viral evasion strategies involve targeting IFN-regulatory
factors (IRF) which culminate in IFN production. HBV
polymerase was reported to impair antiviral innate immune
responses by inhibiting IRF activation in response to TLR3-
and RIG-I- induced pattern recognition receptor signalling
in human hepatoma cell lines [53-55].
Other HBV proteins were shown to target adaptor pro-
teins of the RIG-I pathway.
Regulatory HBx protein binds to beta interferon pro-
moter stimulator 1 (IPS-1) and targets it for inactivation.
The consequence of HBx binding to IPS-1 is inhibition
of double-stranded DNA mediated IFN-β activation in
hepatoma cell lines [56]. Human cell lines studies have
also indicated that adaptor protein mitochondrial anti-
viral signalling (MAVS) is another target for HBx. ByTable 1 Summary of the mechanisms employed by HBV to co
infected cells
Experimental model Mechanism
Human hepatocyte cell line Inhibition of IRF3
Hepatoma cell lines, liver
tumor samples
MAVS degradation
Hepatoma cell lines Blocking DDX3 DEAD box
RNA helicase
Hepatoma cell lines, HBx
transgenic mouse
HBx binding to IPS-1
Hepatoma cell lines Binding and inactivation of mitochond
membrane protein virus-induced
signalling adaptor (VISA)
HBV transgenic mice and hepatoma
cell lines
VSV infection of hepatoma cell
lines and monocyte-derived dendritic
cells from patients with HBV infectionpromoting degradation of MAVS, induction of IFN-β
through the RIG-I pathway is prevented [57].
Another pathway that HBV uses to attenuate the anti-
viral responses of innate immunity is the TLR system. TLR
receptors recognize nucleic acid sequences in degraded
viral particles in endosomal or lysosomal cell compart-
ments. TLR triggering initiates signal transduction path-
ways that promote dendritic cell maturation, production
of key cytokines such as type I IFNs and initiation of adap-
tive immunity [58].
TLR3- and TLR4-activated murine nonparenchymal
liver cells are part of the innate immune response fol-
lowing infection and also possess the ability to suppress
HBV replication via IFN-β induction [59]. The same group
has also shown that the virus has evolved mechanisms to
counteract this effect. HBV virions or viral antigens such
as HBsAg and HBeAg abrogated TLR-induced antiviral ac-
tivity, by suppressing IFN-β production and induction of
IFN-stimulated genes and transcription factors like IRF-3
and NF-κB [60]. The counteractive mechanisms of HBV
that prevent activation of the innate responses are summa-
rized in Table 1.
However, the actual efficacy of these inhibitory mecha-
nisms needs to be established in the context of an in-vivo
infection model. The active inhibition of innate immunity
may not be very robust, since it can be overcome by ex-
ogenous stimulation. In this respect, TLR activation was
shown to control viral replication in vivo in HBV trans-
genic mice [20].
Conclusions
The role of innate immunity in controlling HBV replica-
tion has been neglected for a number of years due to re-




HBV polymerase Inhibition of IFN-β induction [52]
HBx Prevention of IFN-β induction [55]
HBV polymerase Inhibition of IFN-β promoter in
response to RIG-I/MDA5 and TLR3
[51]
HBx Inhibition of IFN-β induction [54]
rial HBx Inhibition of virus-triggered IRF3
activation and IFN-β induction
[53]
HBsAg, HBeAg, or HBV
virions
Suppression of TLR 1-9 induced
activation of IRF3, NF-κB, ERK1/2
and IFN-β production
[58]
Reduced RIG-I expression and
IFN-β production
[50]
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lowing HBV challenge. The ability of antibody responses
to HBV surface antigen to protect adults from HBV chal-
lenge also indicated the importance of adaptive immunity
in controlling viral replication. However, adaptive immunity
alone cannot explain the persistence of HBV during
chronic infection and the immune pathogenesis that char-
acterizes chronic hepatitis B. A better understanding of
how the immune systems works has lead to a reconsider-
ation of the role of innate immunity in HBV infection. Re-
cent research studies mentioned in this review have shown
a different image of HBV pathogenesis, with active mecha-
nisms aimed at inactivating various components of the in-
nate immune system. Thus, the lack of interferon responses
during acute infection seems to be the result of inactivation
of various signalling pathways that normally induce IFN
production in other viral infection. HBx and HBV polymer-
ase are the proteins associated most frequently with inacti-
vation of the TLR and RIG-I pathways and ultimately with
impaired IFN production. These mechanisms may consti-
tute important factors of viral persistence during natural
infection, since in vitro studies have shown that HBV is
sensitive to antiviral properties of IFNs. During the course
of infection HBV also contributes to a sustained immuno-
suppressive state that may favour its replication, since the
number of Tregs increase as disease progresses, which
also decreases the number and function of HBV specific T
lymphocytes.
Other components of the innate immune system that
are targeted by the virus are DCs, NK and NKT cells.
Their activation during acute infection or immunization is
linked to a favourable clinical outcome and subsequent ro-
bust adaptive immune responses. By disrupting innate im-
munity pathways early during infection, the virus also
compromises the quality of adaptive immune response, in
favour of its survival. The interplay between innate and
adaptive immunity for successful control of HBV infection
is complex and needs to be addressed in future thera-
peutic approaches aimed at controlling viral replication.Abbreviations
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